[
  {
    "ts": null,
    "headline": "Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics",
    "summary": "Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finnhub.io/api/news?id=ebb58949247251ae6cfa51204c03afe3a817a9847ac4ab6de975de9cb87d81cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744982120,
      "headline": "Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics",
      "id": 133970048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
      "url": "https://finnhub.io/api/news?id=ebb58949247251ae6cfa51204c03afe3a817a9847ac4ab6de975de9cb87d81cf"
    }
  },
  {
    "ts": null,
    "headline": "Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue",
    "summary": "CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.",
    "url": "https://finnhub.io/api/news?id=0ee908d8d2275c97bf1e21a8060e440fdd46e4506c9f4d25c1c09e781310246c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744977600,
      "headline": "Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue",
      "id": 133964812,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.",
      "url": "https://finnhub.io/api/news?id=0ee908d8d2275c97bf1e21a8060e440fdd46e4506c9f4d25c1c09e781310246c"
    }
  }
]